Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
StockNews.AI · 2 hours
AI Summary
Mirum reported positive Phase 2b data for volixibat in PSC and brelovitug in HDV, plus LIVMARLI PFIC observations at EASL 2026. The VISTAS PSC results support a planned NDA for volixibat in 2H2026, while AZURE-1 topline data and Phase 3 AZURE results due in 2H2026 could expand HDV opportunities and PFIC long-term value.
Sentiment Rationale
Positive phase 2b signals across PSC, HDV, and PFIC, plus an NDA path in 2026, elevate upside potential. Historical parallels show such multi-catalyst pipelines driving mid-term stock appreciation when regulatory timelines align and topline data confirm efficacy.
Trading Thesis
Bullish; expect near-term upside on 2H2026 volixibat NDA and AZURE topline readouts.
Market-Moving
- Volixibat PSC data could serve as a near-term price catalyst for MIRM.
- AZURE-1 HDV topline results may shape HDV franchise perception.
- LIVMARLI PFIC real-world EFS analysis reinforces long-term value.
- FDA pre-NDA meeting in Summer 2026 with NDA submission planned in 2026.
Key Facts
- VISTAS: volixibat in PSC showed rapid, meaningful pruritus relief.
- ItchRO: 56% achieved ≥2-point relief vs 26% placebo.
- sBA: −33.7 µmol/L with placebo-adjusted −35.8 µmol/L.
- NDA for volixibat in PSC targeted for 2H2026.
Companies Mentioned
- Mirum Pharmaceuticals, Inc. (MIRM): Primary driver of data; near-term catalysts include NDA timing and topline AZURE data.
Industry News
Category: Industry News. The release aggregates multiple pipeline readouts and regulatory milestones, signaling near-term catalysts for Mirum’s valuation and potentially shifting sentiment around its rare liver-disease portfolio.